SCHEDULE: Biosion Subsidiary Takes 9.4% Stake in Aclaris Therapeutics

Biosion, Inc.'s wholly-owned subsidiary, Bonita Biotech (HK) Limited, has acquired a 9.4% beneficial ownership stake in Aclaris Therapeutics, Inc. through a warrant exercise.

Summary

• Biosion, Inc. and its wholly-owned subsidiary, Bonita Biotech (HK) Limited, jointly reported beneficial ownership of 11,281,950 shares of Aclaris Therapeutics, Inc. Common Stock.
• This represents 9.4% of Aclaris Therapeutics' total outstanding Common Stock.
• The ownership resulted from Biosion, Inc. assigning an Issuer warrant to Bonita Biotech (HK) Limited on December 9, 2025.
• Bonita Biotech (HK) Limited subsequently exercised this warrant via cashless exercise on December 9, 2025.
• Aclaris Therapeutics, Inc. issued 11,281,950 shares of Common Stock to Bonita Biotech (HK) Limited on December 15, 2025.
• The total shares of Common Stock used for calculation are 119,624,542, comprising 108,342,592 shares outstanding as of November 6, 2025, and the 11,281,950 newly issued shares.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual report of a change in beneficial ownership. While it indicates a significant stake by an institutional investor, it does not provide operational or financial performance data to assess positive or negative sentiment for the issuer.

Positives

• Increased institutional ownership by Biosion, Inc. and its subsidiary, potentially signaling confidence in Aclaris Therapeutics.
• The exercise of the warrant indicates a conversion of a potential future stake into an actual equity position.

Negatives

• Dilution for existing shareholders due to the issuance of 11,281,950 new shares of Common Stock.

Risks

• No specific risks related to Aclaris Therapeutics' operations or financial health are mentioned in this Schedule 13G filing. The filing focuses solely on beneficial ownership reporting.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Aclaris Therapeutics, Inc.'s future performance or strategic direction.

Management Comments

• The filing does not contain notable quotes or paraphrased statements from company management of Aclaris Therapeutics, Inc. It includes certifications from Mingjiu Chen, CEO of Biosion, Inc. and Director of Bonita Biotech (HK) Limited, stating the securities were not acquired for the purpose of changing or influencing control of the issuer.

Industry Context

This filing indicates a significant equity investment by a China-based biotechnology company, Biosion, Inc., into a U.S.-based peer, Aclaris Therapeutics. Such cross-border strategic investments can be common in the biotechnology sector as companies seek to expand their reach, access new technologies, or form alliances. The 9.4% stake suggests a substantial, but non-controlling, interest, potentially paving the way for future collaborations or a deeper strategic partnership.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• Biosion, Inc. assigned an Issuer warrant to its wholly-owned subsidiary, Bonita Biotech (HK) Limited. This is an internal transaction between related parties (parent and subsidiary) concerning Aclaris Therapeutics' securities.

Stakeholder Impact

• Shareholders: Existing shareholders experience dilution due to the issuance of 11,281,950 new shares. The entry of a significant institutional investor (Biosion/Bonita Biotech) could be viewed positively as a vote of confidence or negatively if it signals potential future influence.
• Company (Aclaris Therapeutics): The company now has a significant institutional shareholder, which could influence strategic decisions or provide stability.

Next Steps

• No specific future actions or milestones for Aclaris Therapeutics, Inc. are mentioned in this filing.

Key Dates

Recommendation

The filing reports a significant beneficial ownership stake (9.4%) acquired by Biosion, Inc. through its subsidiary, Bonita Biotech (HK) Limited, via a cashless warrant exercise. While this indicates a substantial investment and potential long-term interest from a strategic player, it also involves dilution for existing shareholders. Without additional information on the strategic intent behind this stake, Aclaris Therapeutics' operational performance, or the terms of the original warrant, a 'hold' recommendation is appropriate. Investors should monitor for further announcements regarding Biosion's intentions or any strategic collaborations.

Keywords

Aclaris Therapeutics, Biosion Inc, Bonita Biotech, Schedule 13G, Beneficial Ownership, Warrant Exercise, Common Stock, Biotechnology, Pharmaceuticals, Equity Stake, SEC Filing